We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vietnam has unveiled a new 10-year pharmaceuticals development plan,
which envisages boosting the domestic sector's market share from 40% to 60%
by 2015.
Teva Pharmaceutical and H. Lundbeck announced that Azilect, a once-daily treatment
for Parkinson's disease (PD) both as monotherapy in patients with early PD and
as an adjunct treatment in moderate to advanced disease, is now available in
the U.K.
Pharmasset and Bukwang Pharm. announce that they have entered into an exclusive
license agreement under which Pharmasset will develop and commercialize Clevudine,
also known as L-FMAU, for the treatment of chronic hepatitis B virus (HBV) infections
in the Americas, Europe, and other select territories.
At a general meeting in Adelaide, shareholders of Bionomics gave their formal
support to the company's acquisition of Iliad Chemicals and a $6 million capital
raising.
Emergent BioSolutions has acquired UK-based Microscience, Ltd., a privately
held vaccine company primarily involved in the research and development of innovative,
proprietary vaccines and immunotherapeutics.
The CEO of a drug firm based in Uganda, Kampala Pharmaceutical Industries, has
warned that the possible abolition of a 10% regional import tariff could lead
to US$25mn in lost government revenues and irreversibly damage the local industry.
Brazil's announcement that it is to break patents on Abbott Laboratories' HIV/AIDS
therapy Kaletra (lopinavir/ritonavir), awaited in recent weeks, appears to mark
the point of no return in negotiations with multinational drug firms.